Session Overview

The main role that DMPK plays in drug discovery is the prediction of drug metabolism and pharmacokinetics in humans. Successful prediction can be expected to reduce the rate of attrition during drug discovery and development. This has led to the recognition that DMPK is an essential component of the drug discovery process. Both this and the need to screen ever greater numbers of compounds have led to major changes in both technology and the process of drug discovery.

Session Chair: Dr Edward Browne

Associate Director of DMPK (Sygnature Discovery)

Ed joined Sygnature Discovery in October 2016 and has over 15 years of experience in the pharmaceutical industry, covering both GLP and non-regulated environments. He worked in a GLP setting for 4 years; firstly with GlaxoSmithKline (GSK) and then Simbec Research in South Wales. Following this he joined GSK’s Neural Pathways Discovery Performance Unit (DPU) in Singapore where he remained for 11 years. Responsible for establishing the DPU’s DMPK group he oversaw the development of in-vitro, in-vivo and bioanalytical labs and supported discovery projects across a range of CNS targets. Ed was also a member of the sites leadership team and held advisory positions supporting discovery research in GSK’s R&D China unit. He has a BSc (Hons) in Chemistry and a PhD in Mass Spectrometry both from the University of Wales, Swansea (now Swansea University).

 

What papers are we looking for?

We are looking for a wide variety of papers on this topic to provide an academic and industry perspective.

Click here to submit a title and abstract 

Interested in presenting?

Get in touch via the below form and we will get back to you as soon as possible.





The Presenters

 

To be confirmed

To be confirmed

To be confirmed

To be confirmed

 

To be confirmed

 

 

To be confirmed

 

 

REGISTER NOW AND SAVE UP TO £210